top
Please input keywords
Order
*Country
한국
미국
일본
중국
영국
호주
프랑스
독일
이탈리아
싱가포르
인도
러시아
캐나다
스위스
기타 국가
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hPD-L1 low MC38
Common name
B-hPD-L1 low MC38 Catalog number    310889
Aliases CD274, PDCD1L1 Disease  Colon carcinoma
Organism
Mouse
Strain  C57BL/6
Tissue types Colon Tissue  Colon

Description


The mouse Pdl1  gene was replaced by human PD-L1 coding sequence in B-hPD-L1 low MC38 cells. Human PD-L1 is expressed on the surface of B-hPD-L1 low MC38 cells.


Application


B-hPD-L1 low MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.


Targeting strategy

Gene targeting strategy for B-hPD-L1 low MC38 cells. The exogenous promoter and human PD-L1 coding sequence was inserted to replace part of murine exon 3. The insertion disrupts the endogenous murine Pdl1 gene, resulting in a non-functional transcript.

Protein expression analysis 

from clipboard


PD-L1 expression analysis in B-hPD-L1 low MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38, B-hPD-L1 MC38 plus and B-hPD-L1 low MC38 cultures were stained with species-specific anti-PD-L1 antibody. Mouse PD-L1 was detectable in wild-type MC38 cells. Human PD-L1 was detectable in B-hPD-L1 low MC38 cells, and human PD-L1 was expressed highly on the surface of B-hPD-L1 MC38 plus cells. The 2-C09 clone of B-hPD-L1 low MC38 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

from clipboard

Subcutaneous homograft tumor growth of B-hPD-L1 low MC38 cells. B-hPD-L1 low MC38 cells (1x106) and wild-type MC38 cells (1x106) were subcutaneously implanted into C57BL/6 mice (female, 6-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hPD-L1 low MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.
The subcutaneous tumor formation of B-hPD-L1 low MC38 cells was slow, and the inoculation dose was recommended to be increased to 1x106.

In vivo efficacy of anti-human PD-1 antibody

from clipboard


Antitumor activity of anti-human PD-1 antibody (pembrolizumab, in house) in B-hPD-1/hPD-L1 mice. (A) Anti-human PD-1 antibody inhibited MC38 tumor growth in B-hPD-1/hPD-L1 mice. Murine colon cancer B-hPD-L1 low MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1 mice (female, 7-week-old, n=6). Mice were grouped when tumor volume reached approximately 100-150 mm3, at which time they were treated with anti-human PD-1 antibody indicated in panel. (B) Body weight changes during treatment. (C) TILs analysis from tumor tissue. Results showed that anti-human PD-1 antibody was efficacious in controlling tumor growth in B-hPD-1/hPD-L1 mice, demonstrating that the B-hPD-1/hPD-L1 mice provide a powerful preclinical model for in vivo evaluation of anti-human PD-1 antibodies. Values are expressed as mean ± SEM.